Drug Design Development and Therapy

Drug Design, Development and Therapy is an international peer-reviewed open access journal published by Dove Medical Press, established in 2007, spanning the spectrum from drug design and development to clinical application, with a 2025 Journal Impact Factor of 6.1《药物设计、开发与治疗》（Drug Design Development and Therapy）由（Dove Medical Press）出版，2007 年创刊，是一份国际性同行评审开放获取期刊，覆盖从药物设计、开发到临床应用的全链条，2025 年影响因子为 6.1

Scope

• The journal spans the spectrum of drug design and development through to clinical applications期刊覆盖从药物设计、开发直到临床应用的全链条
• It is characterized by the rapid reporting of application notes, reviews, original research and clinical studies in all therapeutic areas以快速报道所有治疗领域的应用札记、综述、原创研究与临床研究为特色
• Clinical outcomes, patient safety and programmes for the development and effective, safe and sustained use of medicines are a feature of the journal关注临床结局、患者安全以及药物开发与安全有效持续使用的相关项目
• Papers on drug delivery systems, pharmacokinetics, pharmacogenetics and computational drug discovery appear regularly药物递送系统、药代动力学、药物基因组学与计算药物发现类论文常见于该刊
• The journal is a member of the Committee on Publication Ethics and subscribes to its principles期刊是出版伦理委员会（COPE）成员并遵循其原则
• An accelerated publication route is offered for papers that need rapid dissemination为需要快速传播的论文提供加速出版通道
• All content is open access and free to read, and authors publish under Creative Commons licences全部内容开放获取、免费阅读，论文依知识共享许可协议发布

History

• The journal was established in 2007 by Dove Medical Press, its first volume carrying a single paper该刊由（Dove Medical Press）于 2007 年创办，创刊卷仅刊出 1 篇论文
• It has been published as an open access journal since its launch, and the Directory of Open Access Journals records open access publishing from 2008期刊自创刊起即以开放获取模式出版，开放获取期刊目录记录的开放起始年为 2008 年
• Publication volumes have grown steadily, from a single article in 2007 to more than eight hundred articles in 2026发文量持续增长，从 2007 年的 1 篇增至 2026 年的 800 余篇
• The journal is indexed in the Science Citation Index Expanded, PubMed and Scopus期刊被科学引文索引扩展版、（PubMed）与（Scopus）收录
• Manuscripts average about sixteen weeks from submission to publication, and an article publishing charge applies论文自投稿至发表平均约需 16 周，录用后须缴纳文章出版费
• Its Journal Impact Factor moved from 4.162 in 2021 through 4.319 in 2022 to 6.1 in 2025影响因子由 2021 年的 4.162 经 2022 年的 4.319 变化至 2025 年的 6.1

Editors

• The Editor-in-Chief is Frank Boeckler现任主编为（Frank Boeckler）
• The editorial board is drawn from pharmaceutical research institutions in several countries, and the journal states that additional editorial board members are being recruited编委会成员来自多个国家的药学研究机构，期刊表示正在招募新的编委会成员
• The journal publishes the list of its peer reviewers on its website期刊在网站上公开列出参与评审的同行评审专家名单
• An accelerated publication option is offered to shorten the time from acceptance to publication期刊提供加速出版选项，以缩短录用至发表的时间
• Review follows an anonymous expert peer review process registered with the Directory of Open Access Journals评审采用匿名专家同行评审，并在开放获取期刊目录中登记
• Authors can track the status of their manuscript through the journal's online submission system作者可通过期刊的在线投稿系统查询稿件状态